

## FLORIDA MEDICAID Prior Authorization

#### **VFEND®** (Voriconazole)



(Maximum of 90 Days Approval)

Note: Form must be completed in full. An incomplete form may be returned.

Recipient's Medicaid ID#								Date of Birth (MM/DD/YYYY)																							
Red	ipie	nt's l	ull N	lame			1		1	_								1		1			_			1		1			
Pre	scril	ber's	Full	Name	9																										
Pre	scril	ber's	NPI				1		1	-	ı	1	1										-				1	1	ı		
Pre	scril	ber P	hone	Nun	ber		1		1		1	7							Pres	scri	ber F	ax N	lun	nbe	r		7		ı		
							-																				-				
	Vfer	nd (vo	oricon	azole	;)													ng ta				[				/ml s					
			on of i uatio			nv											200	mg	tab			[		20	0 m	g via	ls (I\	/)			
		, or itali	ualio	101 1	Ю	РУ																				1	bs				kgs
					ı	Direc	ction	าร						_		C	uar	ntity	/30 I	Day	S	•					Wei	ght			kgs
1.	Ple	ase	chec	k all	tha	t ap	ply:	(Vf	end	not	FDA	apı	orov	ed	for	pre	oph	ylad	ctic t	her	ару)										
		Inva	sive	Aspe	ergil	losis	(Or	nly a	ppro	ovec	l ind	licat	ion i	for	prir	na	ry tı	reat	men	t)											
			dide						ic pa	tien	ts																				
	$\vdash$		didia				•	_				. <b>.</b>		: 4	l	_  -  -  -	.l		مالدالد		L II		1								
	H		semir ious i																												
2.	Has		ient							Yes	-	No							•	,		3									
	7	Гуре:					-																		Dat	te:					
3.		٠.	ntifu	ngal	age	ent(s	) ha	s the	e pa	tien	t rec	eive	d in	the	e pa	ast	90	day	s?					_	Du						
	С	)rua	Nam	e:																			Da	tes	of l	Jse:					
	_	_	Reaso		r Die	con																									
	_				Dis	SCOII	unun																n -	4	- 6 1	1					
	L	_	Nam																							Jse:					
		F	Reaso	n foi	r Dis	scon	tinuiı	ng:																							
4.	Site	e(s)	of In	fection	on:																										
5.	Dia	gno	stic t	est(s	s) p	erfo	rme	d ind	clud	e: (c	hec	k all	tha	t ap	ply	ar	nd s	ubr	nit c	ору	of t	est	res	ult	s)						
		Plat	elia A	Aspe	rgillı	us E	IA te	est		Tho	racio	с СТ			] (	Cult	ture(	(s)			Bio	osy									
6.	Vfe	nd p	resc	ribe	d by	<b>/</b> :				Her	nato	logis	st		] (	Onc	olog	gist,	or		Infe	ctio	JS	Dis	eas	e Sp	ecia	alist			
Pre	scril	ber's	Sign	ature	):												_	Da	te: _									_			
RE	QUIF	RED F	OR I			Copi	es of	f med	lical	recoi	rds (i	.e., d	liagno	ostic	eva	alua	– ation											cent	copi	es of	
rela	ted I	abs.					Th	ne pr	ovid	er m	ust r	etair	ı cor	ies	of a	all d	docı	ıme	ntatio	on f	or fiv	e ve	ars	<b>.</b>							

**Call or Fax Information to:** Florida Community Care Prior Authorization

Phone number for non-specialty Prior Authorization: 877-433-7643 Phone number for specialty Prior Authorization: 866-814-5506 Fax number for non-specialty Prior Authorization: 866-255-7569 Fax number for non-specialty Prior Authorization: 866-249-6155

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.



# FLORIDA MEDICAID PROTOCOL VFEND® (Voriconazole)



### **Approved Indications:**

#### 1) Invasive Aspergillosis:

- a. The "Invasive Aspergillosis" diagnosis must be checked.
- b. <u>Initial treatment</u> will be approved for **1 month** in patients suspected of having a life-threatening invasive Aspergillus infection that meet the following criteria:
  - ☐ Have a diagnosis indicating they are immunocompromised or are currently receiving immunosuppressive drugs, AND
  - ☐ Patient has clinical manifestations (symptoms, signs, and radiological features) compatible with the diagnosis of invasive aspergillosis. (Supporting documentation must accompany request.)
- c. The **remaining 60 days of therapy** may be granted upon receipt of a positive **Platelia Aspergillus EIA test** (detects circulating galactomannam antigen), biopsy or culture. A copy of the original lab results is required.
- d. New test results must accompany request for continuation of therapy after initial 90 days of therapy.

#### 2) Treatment Failures:

Patient must have documented treatment failure with one or more of the following (except in the case of invasive aspergillosis):

- ☐ Amphotericin B (Abelcet®, Fungizone®)
- ☐ Flucanozole (Diflucan®)
- ☐ Ketoconazole (Nizoral®)

Indication	PDL Alternatives (Current December 2007)							
Invasive Aspergillosis	Abelcet, amphotericin B, Fungizone							
Candidemia in non-neutropenic patients	Abelcet, amphotericin B, fluconazole, Fungizone							
Candidiasis of the Esophagus	Abelcet, amphotericin B, fluconazole, Fungizone, ketoconazole							
Disseminated candidiasis of the skin, and infections in the bladder wall, abdomen, kidney, and wounds	Abelcet, amphotericin B, fluconazole, Fungizone							
Scedosporium apiospermum and Fusarium species including Fusarium solani	Abelcet, amphotericin B, Fungizone							